FDA Approves Johnson & Johnson Vaccine
US officials have met to approve the single shot vaccine from Johnson & Johnson for emergency use. Trials have shown the shot is 85% effective at preventing serious illness, and 66% effective when moderate cases were involved.
These efficacy rates are lower than the Moderna and the Pfizer vaccines, but they are based on different vaccine technologies, and the J&J vaccine data has taken the new strains into consideration, something that wasn’t present for the other two shot trials.
The J&J vaccine is a single shot that can be stored at regular refrigerator temps, so the logistics strain is lighter than the other two vaccines. The company has committed to 100 million vaccines for the United States by the end of June.
For more updates be sure to check back with the ABN Blog regularly.